Star Combo Pharma Ltd (S66) — Capital Reinvestment Ratio

Latest as of December 2025: 0.51x

Star Combo Pharma Ltd (S66) has a Capital Reinvestment Ratio of 0.51x as of December 2025, meaning it reinvests 1% of its operating cash flow (AU$575.23K) in capital expenditures (AU$295.53K). See Star Combo Pharma Ltd balance sheet quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.51x
Capex / Operating Cash Flow

Operating Cash Flow

AU$575.23K
AUD

Capital Expenditures

AU$295.53K
AUD

Data as of

Dec 2025
Most recent filing

Star Combo Pharma Ltd Capital Reinvestment Ratio (2016–2025)

This chart tracks Star Combo Pharma Ltd's Capital Reinvestment Ratio across 6 annual periods. Check S66 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Star Combo Pharma Ltd (2016–2025)

Year-by-year Capital Reinvestment Ratio for Star Combo Pharma Ltd from 2016 to 2025. For live market cap and broader valuation context, see Star Combo Pharma Ltd (S66) market capitalisation.

Year Reinvestment Ratio Operating CF (AUD) Capital Expenditures YoY Change
2025 0.03x AU$11.94 Million AU$393.72K ▼ -97.7%
2023 1.45x AU$1.88 Million AU$2.73 Million ▼ -98.3%
2022 83.74x AU$87.11K AU$7.29 Million ▲ +282.5%
2021 21.89x AU$331.53K AU$7.26 Million ▲ +7714.6%
2017 0.28x AU$932.20K AU$261.13K ▼ -68.3%
2016 0.88x AU$1.30 Million AU$1.15 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow